Our
Products

INSB200

Drug

INSB200 contains the anesthetic ropivacaine, encapsulated in a proprietary lipid and hydrogel carrier. INSB200 is designed as a single-injection nerve block releasing the ropivacaine slowly at the nerve site, stretching its pain-killing efficacy to 72+ hours.

Product Performance
  • Single-injection for nerve block.
  • 72+ hour duration.
  • Ropivacaine as active drug.
  • Fast recovery of motor function.
  • Quick patient discharge time.
  • Minimal risk of infection.
Competitive Advantages
  • Disruptive technology addressing a true unmet need.
  • Reduces overall opioid consumption.
  • Favorable regulatory environment.
  • Established reimbursement pathway.
  • Strong intellectual property position.
  • Experienced management team and premium manufacturing partners.

InSitu Biologics is currently in the investigational pre-clinical stage.
INSB200 is not yet for sale in any geography.

INSB400

INSB400 is an early-development product focused on local delivery of cancer drugs with a precise elution rate over a pre-programmed period of time.

INSB400 is focused on providing physicians and patients with a product to deliver specific doses of cancer therapeutics to targeted sites in the body.

By eluting anti-cancer drugs in a targeted therapeutic range over a desired period of time, INSB400 is being designed to avoid severe patient adverse events associated with systemic exposure to chemotherapeutic agents.

InSitu Biologics is currently in the investigational pre-clinical stage. INSB400 is not yet for sale in any geography.